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Abstract 
 While there has been new targeted drug therapies released into the market over the recent 
years, pulmonary arterial hypertension (PAH) remains to be a rapidly progressive disease with 
poor prognosis. Over time the arteries stiffen and tighten subsequently leaving the heart to pump 
harder to try and provide enough blood to the body. The extra stress of the increased pumping 
leads to weakening and enlargement of the heart. The endothelin targeted therapy, Letairis 
(ambrisentan), is an oral tablet proven to improve quality of life in patients suffering from PAH, 
WHO Group I – functional class II and III by helping the arteries loosen and relax so that blood 
can flow steadily to the rest of the body. Although Letairis improves the quality of life for 
patients, there is a known serious risk of teratogenicity for females of reproductive potential. The 
risk of teratogenicity is so prominent that the Food and Drug Administration (FDA) required 
Letairis be placed on the risk evaluation and mitigation strategy program (REMS) to continually 
assess the risks and benefits of the product during post-marketing. In order to prevent and reduce 
harm in patients, mechanisms for evaluation and monitoring are vital to drug and patient safety. 
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I. Introduction 
  Pulmonary arterial hypertension (PAH) is a rare progressive disease that affects people 
of all ages, races, and ethnic backgrounds and is caused by the narrowing and/or tightening of 
the pulmonary arteries, which connect the right side of the heart to the lungs. In many cases, as 
PAH develops in patients, blood flow through the pulmonary arteries is restricted and the right 
side of the heart becomes enlarged due to the increased strain of blood being pumped through 
the lungs and into the rest of the body. PAH is considered a chronic disease which currently 
lacks a cure. The World Health Organization (WHO) has classified pulmonary hypertension 
(PH) into 5 groups based on its causes. Group 1 is divided into 2 subgroups: PAH occurring 
with a known cause (Associated PAH) and PAH occurring without a known cause (Idiopathic 
PAH). PH Groups 2 to 5 are referred to as “Secondary PH” because the PH is most likely due 
to a pre-existing condition such as left heart disease, hypoxemia, chronic thrombotic 
pulmonary hypertension (CTEPH), or multifactorial mechanisms (Humbert, Sitbon, & 
Simonneau, 2004). Many who suffer from PAH are misdiagnosed or diagnosed (typically at 
age 5015 years) after the disease has aggressively progressed to an advanced stage leaving the 
patient with few options for treatment (Stamm, Risbano, & Mathier, 2011).  
 During the 1980’s, those living with PAH, especially those with idiopathic PAH, were 
finding that the disease would rapidly progress and lead to heart failure or death and patients 
would see a 2.8-year median survival rate after initial diagnosis (Humbert et al, 2004). Some of 
the first few prospective PAH studies during this time period also showed that the actuarial 
survival rate after diagnosis was 68-77% at 1-year, 40-56% at 3-years, and 22-38% at 5-years 
respectively (Humbert et al, 2004). The prevalence of PAH has increased over the years to 15-
50 cases per million, substantially effecting those of certain high risk groups the most (PAH-
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info.com, 2016). Associated and Secondary PAH have a prevalence of 0.5% in patients infected 
with human immunodeficiency virus (HIV), 2-3.75% in patients with sickle cell disease, and 7-
12% in patients with systemic sclerosis (PAH-info.com, 2016). Idiopathic PAH (IPAH) has an 
incidence rate of 1-2 cases per million however, it is 2 to 4 times more likely to occur in 
women than in men and is thought to account for at least 40% of PAH cases overall (PAH-
info.com, 2016). This IPAH statistic is also supported by the Pulmonary Hypertension 
Association Registry (PHAR) which lists 39% of those registered since 2015 are characterized 
as being diagnosed with IPAH (PHAssociation.org, 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
*The full version of the original paper is on file with the Director of the MPH Program. 
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